Serving mankind with innovative drugs

BeiGene's manufacturing might, R&D prowess, business nous drive expansion

Even without launching a single drug, BeiGene Ltd, a Chinese commercial-stage, research-based biopharmaceutical company listed on the Nasdaq Stock Market, saw its share price surge 220 percent last year, from $30 to $97.

Clearly, investors see immense growth potential in BeiGene, which is pressing ahead with its plan to offer cancer patients the world over innovative, molecularly targeted and immuno-oncology drugs.